CLINICAL / SCIENTIFIC PRESENTATION AND PUBLICATION HIGHLIGHTS
The information contained in each post on this page was factually accurate on the date it was issued and posted.
37th Annual Meeting Society for Immunotherapy of Cancer (SITC) 2022 – Abstracts
Abstract Number 1103 Half-life extended, conditionally active IFNa prodrug induces tumor-selective activation and potent antitumor response Abstract Number 1191 STRO-003 is a novel ROR1-targeted ADC for breast and lung cancer Abstract Number 1359...
Credit Suisse 31st Annual Healthcare Conference – Presentation
64th American Society of Hematology Annual Meeting and Exposition – Abstract
Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
--Results from compassionate use program highlight promising activity of STRO-002 in children with rare form of acute myeloid leukemia, that is highly refractory to all standard-of-care therapies-- SOUTH SAN FRANCISCO, Calif., November 3, 2022 – Sutro Biopharma, Inc....
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., November 2, 2022 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...
2022 Wells Fargo Healthcare Conference – Presentation
Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., August 3, 2022 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...
Sutro Biopharma Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs – Presentation
Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs
SOUTH SAN FRANCISCO, Calif., July 12, 2022 – Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will host a...
22nd Annual Federation of Clinical Immunology Societies (FOCIS) Meeting 2022– Abstract and Poster Presentation
Th42 - Next-generation Immunostimulatory Antibody-drug Conjugate (iADC) Combines Direct Tumor Killing and Innate Immune Stimulation to Provide Protective Anti-Tumor Immunity Presenting Author:Kristin Bedard, PhDVP DiscoverySutro BiopharmaSouth San Francisco,...
